Clinical Trial Update: Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating camrelizumab in combination with apatinib for advanced gastric/GEJ adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Stomach
• Esophagogastric Junction Adenocarcinoma
• Gastric Cancer
• Gastric Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Advanced Gastric Carcinoma | Phase 2 | Status: UNKNOWN